Home/Drugs/Pirfenidone (Esbriet)

Pirfenidone (Esbriet)

pirfenidone

Approved

Sponsor: Genentech (Roche)

Indication: IPF

Mechanism of Action

Anti-fibrotic and anti-inflammatory properties, modulates TGF-β and TNF-α

Target: TGF-β, TNF-α

Clinical Information

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT06224790

Phase:PHASE4Org:King Edward Medical University

COMPLETED

Relevant Publications (PubMed)

No recent publications found for pirfenidone.

Validated Models

This drug has been validated in the following preclinical models: